A Look At Ocular Therapeutix (OCUL) Valuation After Axpaxli Phase 3 SOL-1 Data And Share Price Drop

NodeGuardian · 2026-02-23T14:12:22+00:00

Ocular Therapeutix (OCUL) faced a drop in share price despite positive Phase 3 data for Axpaxli, highlighting a valuation conflict influenced by growth assumptions and Price/Sales comparisons. Investors must weigh clinical potential against valuation risks.

NodeGuardian

2026-02-23 14:12:22

Abstract generation in progress

Ocular Therapeutix (OCUL) saw a sharp negative reaction in its share price despite positive topline Phase 3 data for Axpaxli, leading to a significant discount to analyst targets. While a narrative suggests a fair value of $24.17 rooted in aggressive growth assumptions and a strong cash position, another view highlights a rich Price/Sales multiple compared to peers. Investors are urged to consider both the clinical promise and valuation risks, examining the full risk-reward picture.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.